Effects of ginsenoside compound K combined with cisplatin on the proliferation, apoptosis and epithelial mesenchymal transition in MCF-7 cells of human breast cancer

Pharmaceutical Biology

Volumn 54, Issue 4, 2016, Pages 561-568

  Zhang, Keqiang ^a   Li, Yuwei ^b  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

Anticancer; carcinoma; PI3K Akt pathway

Indexed keywords

20 O BETA DEXTRO GLUCOPYRANOSYL 20 PROTOPANAXADIOL; CISPLATIN; FIBRONECTIN; GINSENOSIDE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; NERVE CELL ADHESION MOLECULE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; ANTINEOPLASTIC AGENT; GINSENOSIDE M1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MONOTHERAPY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; MCF-7 CELL LINE; PATHOLOGY; PHYSIOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; CISPLATIN; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GINSENOSIDES; HUMANS; MCF-7 CELLS;

EID: 84960428992     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2015.1101142     Document Type: Article

References (41)

1. Ahn JH, Kim SB, Sohn HJ, Lee JS, Kang YK, Kun Kim W. 2005. Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines. Breast. 14: 304-309.
2. Caffo O, Lo RG, Sava T, Buti S, Sacco C, Basso U, Zustovich F, Lodde M, Perin A, Facchini G, et al. 2015. Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients. Future Oncol. 11: 965-973.
3. Cancello G, Bagnardi V, Sangalli C, Montagna E, Dellapasqua S, Sporchia A, Iorfida M, Viale G, Barberis M, Veronesi P, et al. 2015. Phase II study with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel with metronomic cyclophosphamide as a preoperative treatment of triple-negative breast cancer. Clin Breast Cancer. 15: 259-265.
4. Cheng Y, Shen LH, Zhang JT. 2005. Anti-amnestic and anti-aging effects of ginsenoside Rg1 and Rb1 and its mechanism of action. Acta Pharmacol Sin. 26: 143-149.
5. Chia S, Gandhi S, Joy AA, Gorr M, Hopkins S, Kondejewski J, Ayoub JP, Califaretti N, Rayson D, Dent SF. 2015. Novel agents and associated toxicities of inhibitors of the PI3k/Akt/ MTOR pathway for the treatment of breast cancer. Curr Oncol. 22: 33-48.
6. Fuertes MA, Castilla J, Alonso C, Pérez JM. 2003. Cisplatin biochemical mechanism of action: From cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem. 10: 257-266.
7. Guo J, Chang L, Zhang X, Pei S, Yu M, Gao J. 2014. Ginsenoside compound K promotes b-amyloid peptide clearance in primary astrocytes via autophagy enhancement. Exp Ther Med. 8: 1271-1274.
8. Guo JQ, Zheng QH, Chen H, Chen L, Xu JB, Chen MY, Lu D, Wang ZH, Tong HF, Lin S. 2014. Ginsenoside Rg3 inhibition of vasculogenic mimicry in pancreatic cancer through downregulation of VE-cadherin/EphA2/MMP9/ MMP2 expression. Int J Oncol. 45: 1065-1072.
9. Ha GH, Park JS, Breuer EK. 2013. TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways. Cancer Lett. 332: 63-73.
10. Jeon M, Lee J, Nam SJ, Shin I, Lee JE, Kim S. 2015. Induction of fibronectin by HER2 overexpression triggers adhesion and invasion of breast cancer cells. Exp Cell Res. 333: 116-126.
11. Joy AA, Ghosh M, Fernandes R, Clemons MJ. 2015. Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines. Curr Oncol. 22: S29-42.
12. Kang KA, Piao MJ, Kim KC, Zheng J, Yao CW, Cha JW, Kim HS, Kim DH, Bae SC, Hyun JW. 2013. Compound K, a metabolite of ginseng saponin, inhibits colorectal cancer cell growth and induces apoptosis through inhibition of histone deacetylase activity. Int J Oncol. 43: 1907-1914.
13. Kim AD, Kang KA, Kim HS, Kim DH, Choi YH, Lee SJ, Kim HS, Hyun JW. 2013. A ginseng metabolite, compound K, induces autophagy and apoptosis via generation of reactive oxygen species and activation of JNK in human colon cancer cells. Cell Death Dis. 4: e750
14. Kim J, Han BJ, Kim H, Lee JY, Joo I, Omer S, Kim YS, Han Y. 2012. Th1 immunity induction by ginsenoside Re involves in protection of mice against disseminated candidiasis due to Candida albicans. Int Immunopharmacol. 14: 481-486.
15. Kwak CW, Son YM, Gu MJ, Kim G, Lee IK, Kye YC, Kim HW, Song KD, Chu H, Park BC, et at. 2015. A bacterial metabolite, compound K, induces programmed necrosis in MCF-7 cells via GSK3b. J Microbiol Biotechnol. 25: 1170-1176.
16. Lau WS, Chen WF, Chan RY, Guo DA, Wong MS. 2009. Mitogen-activated protein kinase (MAPK) pathway mediates the oestrogen-like activities of ginsenoside Rg1 in human breast cancer (MCF-7) cells. Br J Pharmacol. 156: 1136-1146.
17. Lee CS, Bae IH, Han J, Choi GY, Hwang KH, Kim DH, Yeom MH, Park YH, Park M. 2014. Compound K inhibits MMP-1 expression through suppression of c-Src-dependent ERK activation in TNF-α-stimulated dermal fibroblast. Exp Dermatol. 23: 819-824.
18. Lee ES, Choi JS, Kim MS, You HJ, Ji GE, Kang YH. 2011. Ginsenoside metabolite compound K differentially antagonizing tumor necrosis factor-a-induced monocyte-endothelial trafficking. Chem Biol Interact. 194: 13-22.
19. Lee YJ, Jin YR, Lim WC, Park WK, Cho JY, Jang S, Lee SK. 2003. Ginsenoside-Rb1 acts as a weak phytoestrogen in MCF-7 human breast cancer cells. Arch Pharm Res. 26: 58-63.
20. LiW, Liu Y, Zhang JW, Ai CZ, XiangN, LiuHX, Yang L. 2009. Antiandrogen independent prostate cancer effects of ginsenoside metabolites in vitro: Mechanism and possible structure-activity relationship investigation. Arch Pharm Res. 32: 49-57.
21. Lim HK, Bae W, Lee HS, Jung J. 2014. Anticancer activity of marine sponge Hyrtios sp. extract in human colorectal carcinoma RKO cells with different p53 status. Biomed Res Int. 2014: 413575.
22. Liu CH, Tang WC, Sia P, Huang CC, Yang PM, Wu MH, Lai IL, Lee KH. 2015. Berberine inhibits the metastatic ability of prostate cancer cells by suppressing epithelial-to-mesenchymal transition (EMT)-associated genes with predictive and prognostic relevance. Int J Med Sci. 12: 63-71.
23. Liu T, Zhao L, Zhang Y, Chen W, Liu D, Hou H, Ding L, Li X. 2014. Ginsenoside 20(S)-Rg3 targets HIF-1α to block hypoxia-induced epithelial-mesenchymal transition in ovarian cancer cells. PLoS One. 9: e103887.
24. Mailliez A, Baldini C, Van JT, Servent V, Mallet Y, Bonneterre J. 2010. Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients. Br J Cancer. 103: 772-775.
25. Mathiyalagan R, Subramaniyam S, Kim YJ, Kim YC, Yang DC. 2014. Ginsenoside compound K-bearing glycol chitosan conjugates: Synthesis, physicochemical characterization, and in vitro biological studies. Carbohydr Polym. 112: 359-366.
26. Park EH, Kim YJ, Yamabe N, Park SH, Kim HK, Jang HJ, Kim JH, Cheon GJ, Ham J, Kang KS. 2014. Stereospecific anticancer effects of ginsenoside Rg3 epimers isolated from heat-processed American ginseng on human gastric cancer cell. J Ginseng Res. 38: 22-27.
27. Rosati G, Riccardi F, Tucci A, De Rosa P, Pacilio G. 2000. A phase II study of paclitaxel/cisplatin combination in patients with metastatic breast cancer refractory to anthracyclinebased chemotherapy. Tumori. 86: 207-210.
28. Ryu YL, Jung KH, Son MK, Yan HH, Kim SJ, Shin S, Hong S, Hong SS. 2014. Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells. Cancer Lett. 353: 68-77.
29. Saxena A. 2006. Cancer chemotherapy and its side effectmanagement. Nurs J India. 97: 109-110.
30. Seto A, Sugitani I, Toda K, Kawabata K, Takahashi S, Saotome T. 2015. Chemotherapy for anaplastic thyroid cancer using docetaxel and cisplatin: report of eight cases. Surg Today. 45: 221-226.
31. Shimada K, Ishikawa T, Kita K, Narui K, Sugae S, Shimizu D, Tanabe M, Sasaki T, Chishima T, Ichikawa Y, et al. 2015. Neoadjuvant docetaxel/cyclophosphamide in triple-negative breast cancer: Predictive value of class III-b tubulin and non-basal subtype. Anticancer Res. 35: 907-912.
32. Siegel RL, Miller KD, Jemal A. 2015. Cancer statistics, 2015. CA Cancer J Clin. 65: 5-29.
33. Sledge GW, Loehrer PJ, Roth BJ, Einhorn LH. 1988. Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol. 6: 1811-1814.
34. Wang H, Jiang D, Liu J, Ye S, Xiao S, Wang W, Sun Z, Xie Y, Wang J. 2013. Compound K induces apoptosis of bladder cancer T24 cells via reactive oxygen species-mediated p38 MAPK pathway. Cancer Biother Radiopharm. 28: 607-614.
35. Wang Y, Liu J, Zhang Z, Bi P, Qi Z, Zhang C. 2011. Antineuroinflammation effect of ginsenoside Rbl in a rat model of Alzheimer disease. Neurosci Lett. 487: 70-72.
36. Watanabe N, Niho S, Kirita K, Umemura S, Matsumoto S, Yoh K, Ohmatsu H, Goto K. 2015. Vinorelbine and cisplatin in patients with advanced non-small cell lung cancer with interstitial pneumonia. Anticancer Res. 35: 1697-1701.
37. Wu H, Chen J, Wang Q, Jia X, Song S, Yuan P, Liu K, Liu L, Zhang Y, Zhou A, et al. 2014. Ginsenoside metabolite compound K attenuates inflammatory responses of adjuvant-induced arthritis rats. Immunopharmacol Immunotoxicol. 36: 124-129.
38. Yang J, Zeng Z, Peng Y, Chen J, Pan L, Pan D. 2014. IL-7 splicing variant IL-7d5 induces EMT and metastasis of human breast cancer cell lines MCF-7 and BT-20 through activation of PI3K/Akt pathway. Histochem Cell Biol. 142: 401-410.
39. Zghair AN, Sharma R, Sharma AK. 2014. Hormone responsive breast cancer and BRCA1 mutation: mechanism, regulation and iron-mediated effects. Curr Pharm Biotechnol. 15: 1113-1124.
40. Zhang X, Li XR, Zhang J. 2013. Current status and future perspectives of PI3K and mTOR inhibitor as anticancer drugs in breast cancer. Curr Cancer Drug Targets. 13: 175-187.
41. Zheng ZZ, Ming YL, Chen LH, Zheng GH, Liu SS, Chen QX. 2014. Compound K-induced apoptosis of human hepatocellular carcinoma MHCC97-H cells in vitro. Oncol Rep. 32: 325-331.